Intraductal radiofrequency ablation plus biliary stent versus stent alone for malignant biliary obstruction: a systematic review and meta-analysis
Nenhuma Miniatura disponível
Citações na Scopus
Tipo de produção
article
Data de publicação
2024
Título da Revista
ISSN da Revista
Título do Volume
Editora
GEORG THIEME VERLAG KG
Citação
ENDOSCOPY INTERNATIONAL OPEN, v.12, n.1, p.E23-E33, 2024
Resumo
Background and study aims Recurrent biliary stent occlusion and tumor ingrowth remain a major concern among patients with malignant biliary obstruction (MBO) with significant impact on patient morbidity and survival. Intraductal radiofrequency ablation (RFA) has emerged as a promising treatment that seeks to extend stent patency. This study aimed to evaluate the impact of RFA on overall survival (OS) and stent patency among patients with unresectable MBO.Methods A comprehensive search of electronic databases was performed for randomized controlled trials (RCTs) comparing RFA plus biliary stent (RFA+S) versus biliary stent alone (S-alone). Outcomes assessed included overall survival, stent patency, and adverse events (AEs) with mean difference (MD) calculated from pooled proportions. Subgroup analyses were performed for hilar strictures and cholangiocarcinoma (CCA).Results Six RCTs (n=439 patients) were included and demonstrated improved survival among patients who received RFA+S (MD 85.80 days; 95% confidence interval [CI] 35.02-136.58; I 2 =97%; P <0.0009). The pooled MD for total stent patency was 22.25 days (95% CI 17.38-61.87; I (2) =97%; P =0.27). There was no difference in AEs between RFA+S vs S-alone ( P >0.05). On subgroup analyses, RFA+S was associated with improved stent patency (MD 76.73 days; 95% CI 50.11-103.34; I 2 =67%; P <0.01) and OS (MD 83.14 (95% CI 29.52-136.77; I- 2 =97%; P <0.01] for CCA. For hilar strictures, stent patency was improved among patients with RFA+S [MD 83.71 days (95% CI 24.85-142.56; I 2 =84%; P <0.01].Conclusions RFA+S improved OS in the treatment of MBO when compared with S-alone. Moreover, the RFA therapy prolonged stent patency in hilar strictures and CCA, with similar rates of AEs.
Palavras-chave
Strictures, PTCD/PTCS
Referências
- Adler D., Endoscopic stenting for malignant biliary obstruction
- Albers D., 2022, Gastrointest Endosc
- Andrasina T, 2021, EUR J RADIOL, V142, DOI 10.1016/j.ejrad.2021.109830
- Canakis A, 2022, WORLD J GASTRO ENDOS, V14, P581, DOI 10.4253/wjge.v14.i10.581
- Cha BH, 2021, CLIN ENDOSC, V54, P100, DOI 10.5946/ce.2020.254
- Chandrasekar VT., 2021, Mini-invasive Surgery
- Dumonceau JM, 2018, ENDOSCOPY, V50, P910, DOI 10.1055/a-0659-9864
- Gao DJ, 2021, GASTROINTEST ENDOSC, V94, P91, DOI 10.1016/j.gie.2020.12.016
- GRADEpro GDT, 2023, GRADEpro Guideline Development Tool Software
- Hu B, 2016, GASTROINTEST ENDOSC, V83, pAB126, DOI 10.1016/j.gie.2016.03.046
- Inoue T, 2022, CURR ONCOL, V29, P2240, DOI 10.3390/curroncol29040182
- Inoue T, 2022, DIGEST ENDOSC, V34, P345, DOI 10.1111/den.14059
- Kang H, 2022, J HEPATO-BIL-PAN SCI, V29, P469, DOI 10.1002/jhbp.1082
- Kang H, 2021, SURG ENDOSC, V35, P63, DOI 10.1007/s00464-020-07689-z
- Kanno Y., 2023, Gastrointest Endosc
- Khizar H, 2023, J CLIN GASTROENTEROL, V57, P335, DOI 10.1097/MCG.0000000000001810
- Kovács N, 2023, J CLIN MED, V12, DOI 10.3390/jcm12030898
- Liang H., 2015, J Cancer Ther, V06, P981, DOI [10.4236/jct.2015.611106, DOI 10.4236/JCT.2015.611106]
- Moher D, 2016, REV ESP NUTR HUM DIE, V20, P148, DOI 10.14306/renhyd.20.2.223
- Nakai Y, 2020, J GASTROEN HEPATOL, V35, P967, DOI 10.1111/jgh.14955
- Oh D, 2022, J GASTROEN HEPATOL, V37, P2083, DOI 10.1111/jgh.15967
- Pu LZ, 2015, WORLD J GASTROENTERO, V21, P13374, DOI 10.3748/wjg.v21.i47.13374
- Qumseya BJ, 2021, GASTROINTEST ENDOSC, V94, P222, DOI 10.1016/j.gie.2020.12.035
- Sharaiha RZ, 2014, DIGEST DIS SCI, V59, P3099, DOI 10.1007/s10620-014-3264-6
- Sofi AA, 2018, GASTROINTEST ENDOSC, V87, P944, DOI 10.1016/j.gie.2017.10.029
- Song SM, 2022, SURG ENDOSC, V36, P5559, DOI 10.1007/s00464-022-09181-2
- The Cochrane Collaboration Review Manager (RevMan), 2020, Computer program, DOI [10.4103/jips.jips_158_21, DOI 10.4103/JIPS.JIPS_158_21]
- Weismüller TJ, 2021, VISC MED, V37, P39, DOI 10.1159/000513970
- Xia MX, 2022, J HEPATO-BIL-PAN SCI, V29, P693, DOI 10.1002/jhbp.960
- Yan X, 2023, CANCERS, V15, DOI 10.3390/cancers15010039
- Yang JF, 2020, GASTROINTEST ENDOSC, V92, P1204, DOI 10.1016/j.gie.2020.04.075
- Yang JF, 2018, ENDOSCOPY, V50, P751, DOI 10.1055/s-0043-124870
- Zheng X, 2016, J DIGEST DIS, V17, P716, DOI 10.1111/1751-2980.12429